The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Inclusion Criteria: 1. Patients with platinum-sensitive recurrent ovarian cancer confirmed by pathology or histology; 2. Patients who have previously received platinum-based chemotherapy and had a recurrence interval of \> 6 months before the last platinum-based chemotherapy; 3. Patients who have previously received bevacizumab and did not experience progression within 3 months during the use of bevacizumab; 4. Patients who have previously received PARP inhibitors and did not experience progression within 12 months during the use of PARP inhibitors; 5. The patient achieved a complete or partial response after the last platinum-based chemotherapy; 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 7. The patient has a life expectancy of at least 3 months and sufficient organ function; 8. The patient has sufficient bone marrow reserves and organ function, including a creatinine clearance rate of 45 mL/min calculated using the standard Cockcroft and Gault formula; 9. The patient voluntarily agrees to participate in this study and signs an informed consent form. Exclusion Criteria: 1. Patients who are known to be allergic or intolerant to chemotherapy drugs or their excipients and cannot swallow medication; 2. Patients who have undergone major surgery within 28 days prior to enrollment; 3. Patients with central nervous system metastases or a history of seizures within the past 12 months; 4. Uncontrolled hypertension: systolic blood pressure ≥180mmHg, diastolic blood pressure ≥90mmHg; 5. NYHA functional class ≥ III; 6. Patients with severe, uncontrolled systemic diseases; 7. Patients who have received any other investigational drug treatment or participated in any other clinical trials within 30 days prior to enrollment in this study; 8. Pregnant or lactating patients, or patients who cannot guarantee effective contraception during the study treatment period; 9. Patients with poorly controlled neurological or psychiatric disorders or mental illness, poor compliance, and inability to cooperate or describe treatment response; 10. Patients judged by the investigator to be unsuitable for participation in this study.